Recruiting

Testing a new immune-boosting drug combined with an existing cancer treatment

Plain-English translation of NCT06963814 on ClinicalTrials.gov ↗ · Source last updated July 2025 · Translation generated September 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing , a new medication designed to boost your immune system's ability to fight cancer when combined with an existing drug called a PD-1 inhibitor. The medication works by clearing certain immune cells that help tumors hide from your body's defenses, while preserving the immune cells that attack cancer. Researchers believe this combination may be more effective than the PD-1 inhibitor alone for treating various advanced solid tumors.

PD-1 inhibitors have helped many cancer patients, but they don't work for everyone. This trial exists to see if adding this medication to boost your immune response in a different way could help more patients benefit from immunotherapy treatment.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced solid cancer (confirmed by tissue or cell samples)
you have at least one tumor that can be measured on imaging scans
you are in good enough overall health to tolerate treatment (ECOG score of 0 or 1)
your doctors expect you to survive at least 3 more months
you have adequate organ and bone marrow function based on blood tests
if you can become pregnant, you are willing to use reliable birth control for at least 6 months after treatment ends

You likely don't qualify if…

you have cancer that has spread to your brain, spinal cord, or the lining of your brain
your tumor is growing into major blood vessels or attached to them in an unclear way
you have had previous treatment with other CCR8-targeting drugs or certain types of antibody therapies
you have had major surgery (other than biopsies) or significant injury in the past 4 weeks
you have had a different cancer within the past 5 years

What participation looks like

You would receive infusions combined with a PD-1 inhibitor (Keytruda) at study visits. The trial has two phases: first, doctors gradually increase doses to find the right amount (dose escalation), then larger groups receive the dose that worked best (dose expansion). You would need to provide tumor tissue samples for testing and have regular blood tests, imaging scans, and check-ins with your care team to monitor how well the treatment works and watch for side effects. The study is recruiting up to 252 patients total and will test this combination in people with many types of advanced solid tumors.

AI-generated summary from trial data · Sep 11, 2026 · Not medical advice

Trial locations(1 site)

China

Shanghai East Hospital, Shanghai, Shanghai Municipality